Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

The three groups preparing to bid are Lone Star and Kenedix, Bain and Tokyu Fudosan, and KKR, PAG and Nomura Real Estate, two ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Healthcare spending in the U.S. is rising, benefiting companies like Aveanna Healthcare Holdings, which focuses on home-based ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

Bain Capital’s exit leaves Perpetual negotiating with Oaktree-backed financial planner roll-up AZ Next Generation Advisory.